No connection

Search Results

RIGL vs SIBN

RIGL
Rigel Pharmaceuticals, Inc.
BULLISH
Price
$32.43
Market Cap
$599.3M
Sector
Healthcare
AI Confidence
85%
SIBN
SI-BONE, Inc.
NEUTRAL
Price
$14.09
Market Cap
$622.3M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
RIGL
1.66
SIBN
--
Forward P/E
RIGL
6.76
SIBN
-36.94
P/B Ratio
RIGL
1.52
SIBN
3.46
P/S Ratio
RIGL
2.04
SIBN
3.1
EV/EBITDA
RIGL
3.89
SIBN
-30.87

Profitability

Gross Margin
RIGL
82.02%
SIBN
79.57%
Operating Margin
RIGL
33.19%
SIBN
-4.37%
Profit Margin
RIGL
124.72%
SIBN
-9.41%
ROE
RIGL
185.94%
SIBN
-10.97%
ROA
RIGL
23.15%
SIBN
-5.95%

Growth

Revenue Growth
RIGL
21.2%
SIBN
15.0%
Earnings Growth
RIGL
1598.7%
SIBN
--

Financial Health

Debt/Equity
RIGL
0.14
SIBN
0.21
Current Ratio
RIGL
2.42
SIBN
8.55
Quick Ratio
RIGL
2.08
SIBN
7.05

Dividends

Dividend Yield
RIGL
--
SIBN
--
Payout Ratio
RIGL
0.0%
SIBN
0.0%

AI Verdict

RIGL BULLISH

RIGL exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt profile (Debt/Equity 0.14). The company is severely undervalued, trading at $32.43, which is significantly below both its Graham Number ($96.8) and its growth-based intrinsic value ($574.66). While technical trends and insider sentiment are currently bearish, the explosive earnings growth (1598.7% YoY) and a P/E ratio of 1.66 suggest a massive valuation gap. The transition from historical losses to consistent earnings beats indicates a successful pivot to profitability.

Strengths
Extreme undervaluation with a P/E of 1.66 and Price/Book of 1.52
Strong financial health indicated by a Piotroski F-Score of 7/9
Explosive earnings growth (1598.7% YoY) and consistent earnings beats
Risks
Bearish technical trend (0/100) suggesting short-term price pressure
Negative insider sentiment with recent selling activity
Potential for non-recurring gains inflating the reported profit margin (124.72%)
SIBN NEUTRAL

SIBN presents a classic high-risk, high-reward growth profile, characterized by a stable Piotroski F-Score of 4/9 and exceptional liquidity. While the company remains unprofitable with negative net margins, it demonstrates a strong trajectory of narrowing losses and consistent earnings beats (average surprise 40.87%). The balance sheet is fortress-like with a current ratio of 8.55 and low debt, but this is offset by heavy insider selling and a long-term bearish price trend. The disconnect between the 'Strong Buy' analyst consensus and the bearish insider sentiment suggests a speculative environment.

Strengths
Exceptional liquidity with a Current Ratio of 8.55 and Quick Ratio of 7.05
Very strong Gross Margin of 79.57%, indicating high product value and pricing power
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Risks
Negative Profit Margin (-9.41%) and Operating Margin (-4.37%)
Heavy insider selling (15 sell transactions, 0 buys) totaling $4.37M
Long-term price erosion with a 5-year change of -59.4%

Compare Another Pair

RIGL vs SIBN: Head-to-Head Comparison

This page compares Rigel Pharmaceuticals, Inc. (RIGL) and SI-BONE, Inc. (SIBN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile